THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

被引：0
|
作者：
Zhao, M. M. [1 ]
Xiang, Y. [2 ]
Juying, W. [3 ]
Jia, S. H. [4 ]
Chen, B. B. [1 ]
Fan, C. S. [1 ]
机构：
[1] Beijing Med & Hlth Econ Res Assoc, Beijing, Peoples R China
[2] Chongqing Canc Hosp, Chongqing, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[4] Shenyang Pharmaceut Univ, Shenyang, Liaoning, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN99
引用
收藏
页码：S455 / S455
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma.
    Coiffier, B
    Best, JH
    Omnes, LF
    Hornberger, JC
    [J]. BLOOD, 2001, 98 (11) : 864A - 864A
  • [2] Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands
    Groot, MT
    Lugtenburg, PJ
    Hornberger, J
    Huijgens, PC
    Uyl-de Groot, CA
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (03) : 194 - 202
  • [3] Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma
    Best, JH
    Hornberger, J
    Proctor, SJ
    Omnes, LF
    Jost, F
    [J]. VALUE IN HEALTH, 2005, 8 (04) : 462 - 470
  • [4] Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
    Putri, Septiara
    Setiawan, Ery
    Saldi, Siti Rizny F.
    Khoe, Levina Chandra
    Sari, Euis Ratna
    Megraini, Amila
    Nadjib, Mardiati
    Sastroasmoro, Sudigdo
    Armansyah, Armansyah
    [J]. BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [5] Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
    Septiara Putri
    Ery Setiawan
    Siti Rizny F. Saldi
    Levina Chandra Khoe
    Euis Ratna Sari
    Amila Megraini
    Mardiati Nadjib
    Sudigdo Sastroasmoro
    Armansyah Armansyah
    [J]. BMC Health Services Research, 22
  • [6] US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
    Betts, Keith A.
    Thuresson, Per-Olof
    Felizzi, Federico
    Du, Ella X.
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Masaquel, Anthony S.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) : 1003 - 1015
  • [7] COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH RITUXIMAB AND BEVACIZUMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Balmaceda, C.
    Abbott, T.
    Espinoza, M. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S40 - S40
  • [8] Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
    Khor, Sara
    Beca, Jaclyn
    Krahn, Murray
    Hodgson, David
    Lee, Linda
    Crump, Michael
    Bremner, Karen E.
    Luo, Jin
    Mamdani, Muhammad
    Bell, Chaim M.
    Sawka, Carol
    Gavura, Scott
    Sullivan, Terrence
    Trudeau, Maureen
    Peacock, Stuart
    Hoch, Jeffrey S.
    [J]. BMC CANCER, 2014, 14
  • [9] Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
    Sara Khor
    Jaclyn Beca
    Murray Krahn
    David Hodgson
    Linda Lee
    Michael Crump
    Karen E Bremner
    Jin Luo
    Muhammad Mamdani
    Chaim M Bell
    Carol Sawka
    Scott Gavura
    Terrence Sullivan
    Maureen Trudeau
    Stuart Peacock
    Jeffrey S Hoch
    [J]. BMC Cancer, 14
  • [10] A COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN PORTUGAL
    Pinheiro, B.
    Cardoso, M.
    Borges, M.
    Launonen, A.
    Ho, R.
    Miguel, Silva L.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S43 - S44
12345